Neos Therapeutics
Neos Therapeutics was an oral drug delivery pharmaceutical company that developed controlled-release and orally disintegrating tablet ADHD treatments; acquired by Aytu BioPharma in 2021, its ADHD portfolio now anchors Aytu's CNS franchise alongside EXXUA™ for MDD.
- Company typePublic
- Founded2000
- HeadquartersGrand Prairie, United States
- Headcount51–100
- GTM typeB2C
- OfferingHardware or Manufacturing
What Neos Therapeutics does
Neos Therapeutics was a specialty pharmaceutical company built around proprietary oral drug delivery technology, most notably controlled-release and orally disintegrating tablet (ODT) formulations used in branded central nervous system (CNS) therapeutics. Its commercial franchise was anchored on ADHD treatments including Adzenys XR-ODT and Cotempla XR-ODT, serving pediatric and adolescent patients along with the broader ADHD population. The company was originally founded in 2008, headquartered in Grand Prairie, Texas, and listed on NASDAQ under the ticker NEOS before being acquired by Aytu BioPharma (NASDAQ: AYTU) in 2021, ending Neos's standalone operations.
Following the acquisition, Neos's ADHD portfolio was integrated into Aytu's broader CNS-focused pharmaceutical platform, headquartered in Denver, Colorado. The combined entity (Aytu BioPharma, employing 51–100 people) markets three product lines today: the Neos-derived ADHD Portfolio, a Pediatric Portfolio, and EXXUA™, a novel therapeutic for major depressive disorder (MDD) launched in 2025. Revenue is generated through traditional pharmaceutical commercialization: direct distribution to healthcare providers and pharmacies, supported by the RxConnect patient access program. Neos's drug delivery IP and branded product assets remain the foundation of the ADHD franchise within the parent platform.
Neos Therapeutics firmographics
Firmographics- Name
- Neos Therapeutics
- Legal name
- Aytu BioPharma
- Website
- https://neostx.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Neos Therapeutics was an oral drug delivery pharmaceutical company that developed controlled-release and orally disintegrating tablet ADHD treatments; acquired by Aytu BioPharma in 2021, its ADHD portfolio now anchors Aytu's CNS franchise alongside EXXUA™ for MDD.
- Ownership category
- akta.pro rank
Neos Therapeutics industry classification
Industry- Product category
- CNS Pharmaceuticals
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where Neos Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Grand Prairie
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Neos Therapeutics business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain, Infrastructure
Distribution channels1 record
Marketing channels4 records
Neos Therapeutics product offering
Product offeringCore offering
Neos Therapeutics is an oral drug delivery company that develops controlled time-release pharmaceutical technologies. It focuses on central nervous system (CNS) and psychiatric conditions, particularly ADHD, with a portfolio of extended-release medications sold through a direct-to-patient and healthcare provider distribution model. The company is now a subsidiary of Aytu BioPharma following its 2021 acquisition.
Product overview
Aytu BioPharma is a pharmaceutical company offering a focused portfolio of CNS treatments. The product lineup includes EXXUA™ for major depressive disorder (MDD), an ADHD Portfolio for attention deficit/hyperactivity disorder, and a Pediatric Portfolio for younger patients. These novel therapeutics are complemented by patient support programs, with the company positioning itself around innovative medicines and bold actions in the psychiatric and CNS space.
Differentiator
Problem solved
Functional benefit
Brands
- EXXUA: Product for major depressive disorder (MDD)
Products and services
- ADHD Portfolio
Companies that use Neos Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Neos Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Neos Therapeutics partnerships and signals
Strategic signalScale indicators2 records
Recent moves4 records
Expansion highlights3 records
Neos Therapeutics competitors and assessment
Company assessmentDirect peers
- Supernus Pharmaceuticals: Specialty CNS pharma focused on ADHD, epilepsy, and depression. Direct peer as both companies develop differentiated CNS therapeutics targeting similar prescriber bases, with comparable scale and commercial strategy.
- Tris Pharma: Specialty pharma with proprietary oral drug delivery platforms and a strong ADHD portfolio including extended-release and orally disintegrating formulations. Closest direct competitor to Neos's technology-driven ADHD franchise.
- Ironshore Therapeutics: CNS specialty pharma focused on ADHD and related disorders, with proprietary once-daily ADHD therapies. Comparable as a focused CNS specialty player targeting the same prescriber and patient segments.
- Rhodes Pharmaceuticals: Specialty/generic pharma with a substantial ADHD stimulant portfolio. Comparable as a direct competitor in ADHD stimulants, competing on the same payer channels and prescriber base.
- Arbor Pharmaceuticals: Specialty pharma with CNS and ADHD products including a stimulant franchise. Comparable as a CNS specialty player with similar commercial scale and product overlap in ADHD.
Broad incumbents
- Takeda Pharmaceutical (Shire): Acquired Shire, the historical market leader in ADHD (Adderall, Vyvanse, Mydayis). Represents the dominant incumbent whose products and lifecycles shape the competitive environment for specialty ADHD players.
- Eli Lilly: Major pharma with Strattera (atomoxetine) and ongoing CNS pipeline activity. Broad incumbent in MDD/ADHD markets that defines treatment standards and competitive benchmarks.
- Teva Pharmaceutical: Largest generic manufacturer with significant ADHD stimulant generics (including authorized generics of Adderall). Broad incumbent whose pricing and supply decisions heavily influence specialty ADHD economics.
- Janssen Pharmaceuticals (Johnson & Johnson): Major pharma with Concerta (methylphenidate) franchise and broader CNS portfolio. Broad incumbent in ADHD and CNS, serving as a competitor and benchmark for product profile and lifecycle management.
- Pfizer: Large pharma with historical ADHD and CNS assets. Broad incumbent competitor whose strategic decisions in CNS affect the market opportunity for smaller specialty players.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Neos Therapeutics social profiles
Digital presenceNeos Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neos Therapeutics leadership team
Management profileNumber of profiles
Profiles5 records
Neos Therapeutics funding detail
Funding detailFunding overview
Funding rounds9 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neos Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neos Therapeutics
What does Neos Therapeutics do?
Neos Therapeutics is an oral drug delivery company that develops controlled time-release pharmaceutical technologies. It focuses on central nervous system (CNS) and psychiatric conditions, particularly ADHD, with a portfolio of extended-release medications sold through a direct-to-patient and healthcare provider distribution model. The company is now a subsidiary of Aytu BioPharma following its 2021 acquisition.
Is Neos Therapeutics a public or private company?
Neos Therapeutics is a public company. It is classified as corporate owned and is currently operating.
When was Neos Therapeutics founded?
Neos Therapeutics was founded in 2000. It employs 51 to 100 people.
Where is Neos Therapeutics based?
Neos Therapeutics is headquartered in Grand Prairie, United States, in the North America region.
Who are Neos Therapeutics's main competitors?
Direct peers on record are Supernus Pharmaceuticals, Tris Pharma, Ironshore Therapeutics, Rhodes Pharmaceuticals and Arbor Pharmaceuticals. Broad incumbents are Takeda Pharmaceutical (Shire), Eli Lilly, Teva Pharmaceutical, Janssen Pharmaceuticals (Johnson & Johnson) and Pfizer.
Does Neos Therapeutics have an API?
No public API is recorded for Neos Therapeutics.
What industry is Neos Therapeutics in?
Neos Therapeutics's product category is CNS Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its SIC code is 2834.